Meta AnalysisID 6155
中药骨疏康治疗原发性骨质疏松：随机对照试验的贝叶斯网状Meta分析
CRD42022377234
Does Chinese patent herbal medicine Gushukang alone or in combination with western conventional medicine provide therapeutic benefit for patients with primary osteoporosis?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6155
- Evidence Id
- 14713
- Core Evidence Id
- 14713
- Source Meta Analysis Id
- 6134
- Herb2 Meta Analysis Id
- HBMA006134
- Crd Id
- CRD42022377234
- Title
- Chinese herbal product Gushukang for treating primary osteoporosis: a Bayesian network meta-analysis of randomized controlled trials
- Review Question
- Does Chinese patent herbal medicine Gushukang alone or in combination with western conventional medicine provide therapeutic benefit for patients with primary osteoporosis?
- Study Type Included
- Parallel group, randomized controlled trials (RCTs) regardless of blinding or publication types
- Condition Being Studied
- Osteoporosis is a disease in which bone mass declines and the microarchitecture of the bone deteriorates, resulting in increased bone fragility. Osteoporosis is further classified as postmenopausal osteoporosis (Type I), age-related osteoporosis (Type II), and idiopathic osteoporosis. Fractures and their complications are the clinical sequelae of osteoporosis. According to the WHO definition of osteoporosis, the disease affects an estimated 6.3% of men and 21.2% of women over the age of 50 worldwide. Osteoporosis is mainly prevented and treated with basic measures, pharmacological interventions, and rehabilitation therapies. Evidence has been found that Chinese medicine can improve clinical symptoms as well as other effects, but there is insufficient evidence to support its claim that it can prevent osteoporotic fractures. According to a network meta-analysis, Gushukang capsule + CWM ranked first among the Chinese patent medicines for the treatment of postmenopausal osteoporosis in terms of lumbar vertebral and femoral neck bone mineral density (BMD). Thus, we plan to conduct a network meta-analysis to compare the different western medicines combined with the effectiveness and safety of the Chinese herbal product Gushukang for patients with primary osteoporosis.
- Participant
- We will include primary osteoporosis participants. The osteoporosis includes postmenopausal osteoporosis (Type I), age-related osteoporosis (Type II), and idiopathic osteoporosis. There is no restriction on the age, race, or gender of the participants.
- Animal
- Human Disease Modelled
- Intervention
- The intervention of Gushukang should be used alone or as adjunctive therapy to western medicine. We included the dosage form including, but not limited to, capsule and granule.
- Comparator Control
- Eligible control therapy included one or a combination of a placebo, no treatment and conventional western medicine. As far as conventional western medicine (anti-osteoporosis drugs) is concerned, bone resorption inhibitors, bone formation promoters, and other mechanism-based drugs may be used according to the mechanism of action of the drug.
- Main Outcome
- 1) Incidence of fracture or new fracture 2) BMD such as lumbar vertebral and femoral neck
- Outcome Measure
- Additional Outcome
- 1) Pain via visual analogue scale 2) Quality of life measured by a validated tool or instrument 3) Total effective rate with a clear definition 4) Serum alkaline phosphatase (ALP) level 5) Serum bone glaprotein (BGP) level 6) Safety as the incidence of adverse reaction/events (including severe or non-severe)
- Study Method
- Network meta-analysis, Systematic review
- Keyword
- Bayes Theorem; China; Herbal Medicine; Humans; Network Meta-Analysis; Osteoporosis; Randomized Controlled Trials as Topic; gushukang
- Contact
- Jian-Ping Liu [email protected]
- Organisational Affiliation
- Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine
- Funding Source
- Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (No: ZYYCXTD-C-202006)
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-11-19
- Registration Date
- 2022-11-30
- Anticipated Start Date
- 2022-10-01
- Anticipated Completion Date
- 2022-12-31
- Title Cn
- 中药骨疏康治疗原发性骨质疏松：随机对照试验的贝叶斯网状Meta分析
- Title En
- Chinese herbal product Gushukang for treating primary osteoporosis: a Bayesian network meta-analysis of randomized controlled trials
- Bilingual Status
- complete